{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:18:35Z","timestamp":1787019515822,"version":"build-2736575974"},"reference-count":64,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To determine whether the leukemia-associated Wilms tumor antigen (WT1) contributes to a graft-versus-leukemia (GVL) effect after allogeneic stem-cell transplantation (SCT) for acute lymphoblastic leukemia (ALL), we studied CD8+ T-cell responses to WT1 in 10 human lymphocyte antigen (HLA)\u2013A*0201\u2013positive ALL patients during the early phase of immune recovery after SCT (days 30-120). Seven of 10 patients had detectable WT1 expression in their peripheral blood (PB) before SCT by quantitative reverse-transcription polymerase chain reaction. Using WT1\/HLA-A*0201 tetramers and intracellular interferon-\u03b3 (IFN-\u03b3) staining, WT1+ CD8+ T-cell responses after SCT were found only in patients with detectable WT1 expression before SCT (5 of 7 vs. 0 of 3; P &lt; .05). To monitor the kinetics of WT1+ CD8+ T-cell responses and disease regression after SCT, absolute WT1+ CD8+ T-cell numbers and WT1 expression were studied for each time point. The emergence of WT1+ CD8+ T cells was associated with a decrease in WT1 expression, suggesting a WT1-driven GVL effect. Loss of WT1+ CD8+ T-cell responses was associated with reappearance of WT1 transcripts, consistent with a molecular relapse (P &lt; .001). WT1+ CD8+ T cells had a predominantly effector\u2013memory phenotype (CD45RO+ CD27\u2212CD57+) and produced IFN-\u03b3. Our results support the immunogenicity of WT1 after SCT for ALL and highlight the potential for WT1 vaccines to boost GVL after SCT for ALL.<\/jats:p>","DOI":"10.1182\/blood-2007-03-076844","type":"journal-article","created":{"date-parts":[[2007,5,15]],"date-time":"2007-05-15T21:42:48Z","timestamp":1179265368000},"page":"1924-1932","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":145,"title":["Graft-versus-leukemia effects associated with detectable Wilms tumor-1\u2013specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"110","author":[{"given":"Katayoun","family":"Rezvani","sequence":"first","affiliation":[{"name":"Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes S. M.","family":"Yong","sequence":"additional","affiliation":[{"name":"Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[{"name":"Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Keyvanfar","sequence":"additional","affiliation":[{"name":"Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Gostick","sequence":"additional","affiliation":[{"name":"Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Price","sequence":"additional","affiliation":[{"name":"Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;"},{"name":"Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Douek","sequence":"additional","affiliation":[{"name":"Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Barrett","sequence":"additional","affiliation":[{"name":"Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111715162329000_B1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation.","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"2019111715162329000_B2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"2019111715162329000_B3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia.","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"2019111715162329000_B4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","article-title":"Donor leukocyte infusions in acute lymphocytic leukemia.","volume":"26","author":"Collins","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2019111715162329000_B5","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V87.6.2195.bloodjournal8762195","article-title":"Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.","volume":"87","author":"Slavin","year":"1996","journal-title":"Blood"},{"key":"2019111715162329000_B6","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1182\/blood.V91.6.2197","article-title":"Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.","volume":"91","author":"Warren","year":"1998","journal-title":"Blood"},{"key":"2019111715162329000_B7","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4049\/jimmunol.158.2.560","article-title":"Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL.","volume":"158","author":"Dolstra","year":"1997","journal-title":"J Immunol"},{"key":"2019111715162329000_B8","first-page":"223","article-title":"Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis.","volume":"68","author":"Sugiyama","year":"2002","journal-title":"Methods Mol Med"},{"key":"2019111715162329000_B9","first-page":"1060","article-title":"Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.","volume":"9","author":"Menssen","year":"1995","journal-title":"Leukemia"},{"key":"2019111715162329000_B10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000040973","article-title":"WT1 gene expression in childhood leukemias.","volume":"102","author":"Niegemann","year":"1999","journal-title":"Acta Haematol"},{"key":"2019111715162329000_B11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/sj.leu.2404047","article-title":"Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.","volume":"20","author":"Boublikova","year":"2006","journal-title":"Leukemia"},{"key":"2019111715162329000_B12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002510050018","article-title":"Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product.","volume":"51","author":"Oka","year":"2000","journal-title":"Immunogenetics"},{"key":"2019111715162329000_B13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood.V95.1.286","article-title":"HLA class I-restricted lysis of leukemia cells by a CD8 + cytotoxic T-lymphocyte clone specific for WT1 peptide.","volume":"95","author":"Ohminami","year":"2000","journal-title":"Blood"},{"key":"2019111715162329000_B14","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.V95.7.2198","article-title":"Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.","volume":"95","author":"Gao","year":"2000","journal-title":"Blood"},{"key":"2019111715162329000_B15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1006637529995","article-title":"Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination.","volume":"20","author":"Tsuboi","year":"2000","journal-title":"J Clin Immunol"},{"key":"2019111715162329000_B16","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.4049\/jimmunol.164.4.1873","article-title":"Cancer immunotherapy targeting Wilms' tumor gene WT1 product.","volume":"164","author":"Oka","year":"2000","journal-title":"J Immunol"},{"key":"2019111715162329000_B17","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V96.4.1480","article-title":"Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.","volume":"96","author":"Gaiger","year":"2000","journal-title":"Blood"},{"key":"2019111715162329000_B18","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2003-01-0150","article-title":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.","volume":"102","author":"Rezvani","year":"2003","journal-title":"Blood"},{"key":"2019111715162329000_B19","doi-asserted-by":"crossref","first-page":"8799","DOI":"10.1158\/1078-0432.CCR-05-1314","article-title":"T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.","volume":"11","author":"Rezvani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2019111715162329000_B20","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2002-01-0163","article-title":"CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.","volume":"100","author":"Scheibenbogen","year":"2002","journal-title":"Blood"},{"key":"2019111715162329000_B21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.leu.2403186","article-title":"Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity.","volume":"18","author":"Mail\u00e4nder","year":"2004","journal-title":"Leukemia"},{"key":"2019111715162329000_B22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/BF02983241","article-title":"Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.","volume":"78","author":"Oka","year":"2003","journal-title":"Int J Hematol"},{"key":"2019111715162329000_B23","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111715162329000_B24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1074-7613(00)80093-X","article-title":"Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts.","volume":"11","author":"Goldrath","year":"1999","journal-title":"Immunity"},{"key":"2019111715162329000_B25","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.4049\/jimmunol.165.5.2458","article-title":"Survival and homeostatic proliferation of naive peripheral CD4+ T cells in the absence of self peptide:MHC complexes.","volume":"165","author":"Clarke","year":"2000","journal-title":"J Immunol"},{"key":"2019111715162329000_B26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1084\/jem.192.4.549","article-title":"Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells.","volume":"192","author":"Cho","year":"2000","journal-title":"J Exp Med"},{"key":"2019111715162329000_B27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2006.04.569","article-title":"Autoimmunity during lymphopenia: a two-hit model.","volume":"120","author":"Krupica","year":"2006","journal-title":"Clin Immunol"},{"key":"2019111715162329000_B28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbmt.2003.08.011","article-title":"Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.","volume":"10","author":"Nakamura","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111715162329000_B29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.bmt.1703928","article-title":"Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.","volume":"31","author":"Solomon","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"2019111715162329000_B30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.leu.2401953","article-title":"Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.","volume":"15","author":"Thiede","year":"2001","journal-title":"Leukemia"},{"key":"2019111715162329000_B31","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood.V90.5.1751","article-title":"Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.","volume":"90","author":"Diamond","year":"1997","journal-title":"Blood"},{"key":"2019111715162329000_B32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/146532402317251509","article-title":"Flow cytometric quantitation and characterization of the T-lymphocyte memory response to CMV in healthy donors.","volume":"4","author":"Hensel","year":"2002","journal-title":"Cytotherapy"},{"key":"2019111715162329000_B33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.274.5284.94","article-title":"Phenotypic analysis of antigen-specific T lymphocytes.","volume":"274","author":"Altman","year":"1996","journal-title":"Science"},{"key":"2019111715162329000_B34","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program.","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"2019111715162329000_B35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34 + cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"key":"2019111715162329000_B36","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2002-06-1831","article-title":"The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.","volume":"101","author":"Ogawa","year":"2003","journal-title":"Blood"},{"key":"2019111715162329000_B37","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program.","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"2019111715162329000_B38","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood.V96.9.3126","article-title":"UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition.","volume":"96","author":"Vogt","year":"2000","journal-title":"Blood"},{"key":"2019111715162329000_B39","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.4049\/jimmunol.164.5.2807","article-title":"The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen.","volume":"164","author":"Warren","year":"2000","journal-title":"J Immunol"},{"key":"2019111715162329000_B40","first-page":"3771","article-title":"Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy.","volume":"56","author":"Zhu","year":"1996","journal-title":"Cancer Res"},{"key":"2019111715162329000_B41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/sj.leu.2403539","article-title":"Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.","volume":"19","author":"Wu","year":"2005","journal-title":"Leukemia"},{"key":"2019111715162329000_B42","first-page":"761s","article-title":"WT1-specific serum antibodies in patients with leukemia.","volume":"7","author":"Gaiger","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2019111715162329000_B43","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/nm1312","article-title":"Lymphopenia and interleukin-2 therapy alter homeostasis of CD4 + CD25 + regulatory T cells.","volume":"11","author":"Zhang","year":"2005","journal-title":"Nat Med"},{"key":"2019111715162329000_B44","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.4049\/jimmunol.174.11.6571","article-title":"The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance.","volume":"174","author":"Fry","year":"2005","journal-title":"J Immunol"},{"key":"2019111715162329000_B45","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbmt.2005.08.032","article-title":"Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","volume":"11","author":"Reddy","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111715162329000_B46","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111715162329000_B47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-09-3344","article-title":"Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.","volume":"105","author":"Alpdogan","year":"2005","journal-title":"Blood"},{"key":"2019111715162329000_B48","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/blood-2003-11-3789","article-title":"Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution.","volume":"104","author":"Fry","year":"2004","journal-title":"Blood"},{"key":"2019111715162329000_B49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10428190310001609898","article-title":"Molecular analysis of T-cell repertoire in patients with graft-versus-host disease after allogeneic stem cell transplantation.","volume":"45","author":"Tsutsumi","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2019111715162329000_B50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbmt.2003.10.002","article-title":"Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.","volume":"10","author":"Jones","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111715162329000_B51","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.bmt.1704442","article-title":"Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.","volume":"33","author":"Mohty","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"2019111715162329000_B52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2141.2005.05843.x","article-title":"Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.","volume":"132","author":"Matsushita","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111715162329000_B53","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1200\/JCO.2003.10.503","article-title":"Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.","volume":"21","author":"Cilloni","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111715162329000_B54","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2141.2004.04952.x","article-title":"WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients\u2014results from a single-centre study.","volume":"125","author":"\u00d8stergaard","year":"2004","journal-title":"Br J Haematol"},{"key":"2019111715162329000_B55","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","article-title":"Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells.","volume":"101","author":"Brenchley","year":"2003","journal-title":"Blood"},{"key":"2019111715162329000_B56","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1084\/jem.186.9.1407","article-title":"Phenotypic and functional separation of memory and effector human CD8+ T cells.","volume":"186","author":"Hamann","year":"1997","journal-title":"J Exp Med"},{"key":"2019111715162329000_B57","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"2019111715162329000_B58","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.4049\/jimmunol.168.11.5455","article-title":"Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8 + T cell response.","volume":"168","author":"Wills","year":"2002","journal-title":"J Immunol"},{"key":"2019111715162329000_B59","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.4049\/jimmunol.174.10.6088","article-title":"Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T lymphocytes during active, latent, and resolved infection and its relation with CD57.","volume":"174","author":"Ibegbu","year":"2005","journal-title":"J Immunol"},{"key":"2019111715162329000_B60","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J Clin Invest"},{"key":"2019111715162329000_B61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14653240701218524","article-title":"Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity.","volume":"9","author":"Rezvani","year":"2007","journal-title":"Cytotherapy"},{"key":"2019111715162329000_B62","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.4049\/jimmunol.174.12.8210","article-title":"Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.","volume":"174","author":"Gannag\u00e9","year":"2005","journal-title":"J Immunol"},{"key":"2019111715162329000_B63","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1073\/pnas.0530192100","article-title":"Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.","volume":"100","author":"Marijt","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111715162329000_B64","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/10563","article-title":"Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.","volume":"5","author":"Mutis","year":"1999","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/6\/1924\/1479133\/zh801807001924.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/6\/1924\/1479133\/zh801807001924.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:31:27Z","timestamp":1683826287000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/6\/1924\/24073\/Graftversusleukemia-effects-associated-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,15]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,9,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-03-076844","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,15]]}}}